Physician profile
Jonathon Michael Mccrary
NPI 1851764856
$1,814.06
in general payments reported to CMS, 2019-2025
26 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.74 · 2023: $523 · 2024: $944 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $225.61 | 2023-2025 | Verquvo, Capvaxive |
| Atricure, INC. | $199.68 | 2024 | |
| Novo Nordisk INC | $176.81 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $158.17 | 2023-2024 | Andexxa, Wainua |
| Alnylam Pharmaceuticals INC. | $152.37 | 2023-2025 | Onpattro |
| Amgen INC. | $137.35 | 2023-2025 | Repatha, Repatha |
| Abbott Laboratories | $107.87 | 2024 | Jot Dx, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.95 | 2023-2025 | Lifevest |
| Daiichi Sankyo INC. | $72.61 | 2023-2025 | Injectafer |
| Boston Scientific Corporation | $71.76 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.29 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $53.04 | 2025 | |
| Medtronic, INC. | $42.47 | 2022-2023 | Vanta Adaptivestim |
| Sanofi-Aventis U.S. LLC | $35.81 | 2023 | |
| Lilly USA, LLC | $32.09 | 2025 | Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $28.99 | 2023 | Inpefa |
| Cvrx, INC. | $23.00 | 2024 | Barostim Neo System |
| Baxter Healthcare | $20.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Cardiac Dimensions, INC. | $18.90 | 2024 | |
| Silk Road Medical, INC. | $18.74 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Esperion Therapeutics, INC. | $18.65 | 2024 | Nexletol |
| Medexus Pharma, INC. | $17.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $14.86 | 2024 | Arcalyst |
| Chiesi USA, INC. | $13.57 | 2023 | Kengreal |
| Impulse Dynamics (USA) INC. | $7.61 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.